RxDoctor Payments Data

Marion Crisostomo, APRN

Psychiatric/Mental Health · Chandler, AZNPI 1558134353

Payments from drug & device makers

$3,033in general payments, 2019–2025

Across 91 payments — averaging $33.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$760
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$574
  • Axsome Therapeutics, Inc.$353
  • Johnson & Johnson$345
  • Neurocrine Biosciences, Inc.$214
  • Vanda Pharmaceuticals Inc.$191
  • plus $597 from 13 others

What the payments were for

  • Food & beverage$3,033100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,033 in reported general payments places this provider in the 85th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Medicare billing

Part B allowed, 2024
$10,902
Medicare patients
22
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl95$135,181
VraylarCariprazine Hcl20$30,502
Aripiprazole27$1,664
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine16$703
Fluoxetine Hcl25$688
Bupropion XlBupropion Hcl33$401
Hydroxyzine Pamoate27$356
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine13$324
Buspirone Hcl11$315
Escitalopram Oxalate45$312
Lamotrigine29$282
Alprazolam28$187
Trazodone Hcl24$171
Duloxetine Hcl11$99
Sertraline Hcl21$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$345$135,18195 claims
AbbVieVraylar$760$30,50220 claims
Almatica Pharma LLCSertraline Hcl$64$9021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →